Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Polysulfated Glycosaminoglycan

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Liquid (Solution) American Regent, Inc. Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Image coming soon
Polysulfated Glycosaminoglycan

Polysulfated Glycosaminoglycan

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Liquid (Solution) Rx required 100% storefront ready

Species: Both

Manufacturer: American Regent, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Polysulfated Glycosaminoglycan

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints. Species commonly shown: Both, Horse, Not For Meat Production, Adults.

Generic name
Polysulfated Glycosaminoglycan
Brand names
Adequan® Injectable, Adequan® i.m. Multi-Dose Adequan® i.m., Adequan® Canine, Adequan Canine
Manufacturer
American Regent, Inc.
Species
Both, Horse, Not For Meat Production, Adults, Dog, No Use Class Stated Or Implied
Dosage forms
Liquid (Solution)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Adequan® Injectable Adequan® i.m. Multi-Dose Adequan® i.m. Adequan® Canine Adequan Canine Adequan i.m.
Dosage forms
Liquid (Solution)

Indications / Uses

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eating, Lethargy (see also Central nervous system depression in Neurological).

FAQ

Both, Horse, Not For Meat Production, Adults, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Liquid (Solution)

Related Conditions

Lameness (undifferentiated) Trauma (HBC, falls, bite wounds)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only
  • Not for intra-articular use
  • Do not mix with other drugs or solvents
  • PSGAG is a synthetic heparinoid
  • do not use in dogs with known or suspected bleeding disorders
  • Do not exceed recommended dose or regimen
  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Not for use in horses intended for food
  • Safe use in breeding animals has not been established
  • Do not use in horses intended for human consumption
  • Safe use in breeding animals or in lactating mares has not been established
  • For Intramuscular use in horses only

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: American Regent, Inc.
Form: Liquid (Solution)
Identifiers:
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Source metadata:

Warnings / Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Diarrhea Neurologic (2) · Unsteady walking (ataxia), Depression Behavior (1) · Anxiety Other (25) · Falling, Facial oedema, Excessive chewing, licking and/or grooming
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Dog (27) Cat (5)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

7

FOI

4

Adequan® Canine

SPL · SPL

Open original
FDA Structured Product Label

Adequan® Canine

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
141-038
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Dog, No Use Class Stated Or Implied
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.

Dogs

Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan® i.m. Multi-Dose

SPL · SPL

Open original
FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® i.m.

SPL · SPL

Open original
FDA Structured Product Label

Adequan® i.m. Multi-Dose Adequan® i.m.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
140-901
Status
RX
Form
Liquid (Solution)
Route
Intramuscular
Species
Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

Adequan® Injectable

SPL · SPL

Open original
FDA Structured Product Label

Adequan® Injectable

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
American Regent, Inc.
NADA
136-383
Status
RX
Form
Liquid (Solution)
Route
Intra-Articular
Species
Horse, Not For Meat Production
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.

Horses

Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Adequan Canine SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Adequan Canine. Use the source link for the full official labeling record.

Adequan i.m. SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Adequan i.m.. Use the source link for the full official labeling record.

Adequan i.m. SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Adequan i.m.. Use the source link for the full official labeling record.

N141038_Orig_7_15_1997.pdf

FOI · FOI

Open original

N140901_Supp_9_12_1996.pdf

FOI · FOI

Open original

N140901 Orig_11_11_1989.pdf

FOI · FOI

Open original

UCM367650.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Adequan Canine Adequan i.m.
Manufacturer mapping: American Regent, Inc.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Adults, Dog, Horse
Rx/OTC: RX
Form/route: Liquid (Solution) • Intra-Articular, Intramuscular
Applications: NADA 141-038 • NADA 140-901 • NADA 136-383
NDC: Packages 10797-959-01 10797-975-01 10797-975-02 10797-995-01 10797-995-70 • Products 10797
Documents: 4 (FOI: 4) • SPL: 4 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 66 • Cat 9 • View
Case summaries: 14 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Loss of appetite (1) Facial oedema (1) Excessive chewing, licking and/or grooming (1) Elevated symmetrical dimethylarginine (1) Elevated gamma-glutamyl transferase (1) Elevated creatinine (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 136383 NADA: 140901 NADA: 141038 NDC Package: 10797-959-01 NDC Package: 10797-975-01 NDC Package: 10797-975-02 NDC Package: 10797-995-01 NDC Package: 10797-995-70 NDC Product: 10797
Package NDC Product NDC Form / Route Status
10797-959-01 10797 -
10797-975-01 10797 -
10797-975-02 10797 -
10797-995-01 10797 -
10797-995-70 10797 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Adequan Canine SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Adequan i.m. SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N141038_Orig_7_15_1997.pdf • FOI summary • Official • June 28, 2018
    FDA FOI summary for application 141038
  • N140901 Orig_11_11_1989.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • N140901_Supp_9_12_1996.pdf • FOI summary • Official • Dec. 7, 2017
    FDA FOI summary for application 140901
  • UCM367650.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 136383

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 42 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy - NOS, Lethargy (see also Central nervous system depression in 'Neurological'), Not eat… (Clinical, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-12)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-04-11)
  • contraindications: Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a … (Official, 2026-02-12)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-05-05)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-05-03)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-05-02)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-29)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-28)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-27)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-26)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-25)
  • indications: Adequan is recommended for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses… (Official, 2026-04-22)
  • manufacturer_name: American Regent, Inc. (Official, 2026-05-05)
  • manufacturer_name: American Regent, Inc. (Official, 2026-05-03)
  • manufacturer_name: American Regent, Inc. (Official, 2026-05-02)
  • manufacturer_name: American Regent, Inc. (Official, 2026-04-29)
  • manufacturer_name: American Regent, Inc. (Official, 2026-04-28)
  • manufacturer_name: American Regent, Inc. (Official, 2026-04-27)
  • manufacturer_name: American Regent, Inc. (Official, 2026-04-26)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Adequan® Canine
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) • Intramuscular
Label highlights
Official documents
American Regent, Inc. NADA 141-038 Approved Jun 28, 2018
Adequan® i.m. Multi-Dose Adequan® i.m.
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) • Intramuscular
Label highlights
Official documents
American Regent, Inc. NADA 140-901 Approved Dec 7, 2017
Adequan® Injectable
RX
Polysulfated Glycosaminoglycan
Liquid (Solution) • Intra-Articular
Label highlights
Official documents
American Regent, Inc. NADA 136-383 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each mL of solution contains 100 mg polysulfated glycosaminoglycan.
Dogs
Indication
For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
Dosage
2 milligrams per pound of body weight (0.02 mL/lb or 1 mL/ 50 lb) by intramuscular injection. Administer intramuscularly twice weekly for up to 4 weeks (maximum of 8 injections).
Limitations
PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Adults
Composition / specifications
Each mL of solution contains 100 milligrams polysulfated glycosaminoglycan available in 5-mL single dose ampules or 20-, 30-, or 50-mL multi-dose vials.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Dosage
500 milligrams intramuscularly (carpal and hock) every 4 days for 28 days. Injection site must be thoroughly cleansed prior to injection.
Limitations
Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production
Composition / specifications
Each 1-milliliter ampule of sterile aqueous solution contains 250 milligrams of polysulfated glycosaminoglycan.
Horses
Indication
Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses.
Dosage
250 milligrams intra-articular use once a week for 5 weeks. The joint area must be shaved, cleaned, and sterilized as in a surgical procedure prior to injection. If the joint reacts with excessive inflammation, after intra-articular treatment, cease therapy.
Limitations
Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal joint in horses. Polysulfated glycosaminoglycan is for the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Not for use in horses intended for food. Safe use in breeding animals has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption. Safe use in breeding animals or in lactating mares has not been established. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Intramuscular use in horses only. Not for intra-articular use. Do not mix with other drugs or solvents. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders. Do not exceed recommended dose or regimen. Do not mix with other drugs or solvents. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Depression (1) • Dog

Showing top 5 for Neurologic.

Behavior
Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Falling (1) • Dog Facial oedema (1) • Dog Excessive chewing, licking and/or grooming (1) • Dog Eosinopenia (1) • Dog Elevated symmetrical dimethylarginine (1) • Cat
Show more (20)
Elevated globulins (1) • Dog Elevated gamma-glutamyl transferase (1) • Dog Elevated creatinine (1) • Cat Elevated blood urea nitrogen (1) • Dog Discomfort NOS (1) • Dog Difficulty standing (1) • Dog Dehydration (1) • Dog Decreased haematocrit (1) • Cat Decreased drinking (1) • Dog Decreased body temperature (1) • Dog Death by euthanasia (1) • Dog Death (1) • Cat Congestion of mucous membrane (1) • Dog Collapse NOS (1) • Dog Chewing disorder (1) • Dog Cardiac arrest (1) • Cat Bone and joint disorder NOS (1) • Dog Anaphylaxis (1) • Dog Abnormal tail posture (1) • Dog Abnormal radiograph finding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - German, Female, 11 year, 20.865 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Vomiting, Not eating, Tiredness (lethargy), Reluctant to move, Seizure NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075421
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 20.865 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Vomiting Not eating Tiredness (lethargy) Reluctant to move Seizure NOS
Outcomes: Ongoing

Dog, ['Retriever - Golden', 'Beagle', 'Chow Chow'], Male, 11 year, 19.504 kilogram • Drug: MSK, Unassigned, Subcutaneous, Frequency: 14 per day • Reactions: Unsteady walking (ataxia), Vestibular disorder NOS, Weight loss, Head tilt - neurological disorder, Low vision… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075189
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 19.504 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Unassigned
  • Frequency: 14 per day
Reactions Reported:
Unsteady walking (ataxia) Vestibular disorder NOS Weight loss Head tilt - neurological disorder Low vision Urinary incontinence Unable to rise Urinary tract infection Polydipsia Horizontal nystagmus Generalised weakness Depression
Outcomes: Ongoing

Dog, Terrier - Irish Soft-coated Wheaten, Male, 12 year, 21.319 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.90 mL per dose • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-074219
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 21.319 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 0.90 mL per dose
Reactions Reported:
Death
Outcomes: Died

Dog, Retriever - Chesapeake Bay, Female, 4 year, 35.743 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 1.57 mL per dose • Reactions: Vomiting, Loss of appetite, Loose stool, Neutrophilia, Dehydration… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-074217
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 35.743 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 1.57 mL per dose
Reactions Reported:
Vomiting Loss of appetite Loose stool Neutrophilia Dehydration Low platelet count
Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Male, 5 year, 39.463 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Limb non-weight bearing, Bone and joint disorder NOS, Other abnormal test result NOS, Abnormal radiograph finding, Urinary tract obstruction/blockage… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-074601
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 39.463 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Limb non-weight bearing Bone and joint disorder NOS Other abnormal test result NOS Abnormal radiograph finding Urinary tract obstruction/blockage Discomfort NOS Walking difficulty Death by euthanasia Osteochondritis dissecans Urolithiasis
Outcomes: Euthanized

Dog, Retriever - Labrador, Male, 11 year, 37.83 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 1.60 mL per dose • Reactions: Anaphylaxis, Seizure NOS, Vomiting, Collapse NOS, Loose bowel… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-073464
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 37.830 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intramuscular
  • Form: Solution
  • Dose: 1.60 mL per dose
Reactions Reported:
Anaphylaxis Seizure NOS Vomiting Collapse NOS Loose bowel Congestion of mucous membrane Low blood pressure Decreased body temperature
Outcomes: Recovered/Normal

Dog, ['Pit Bull', 'Dog (unknown)'], Female, 11.5 year, 37.376 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Joint swelling, Bone and joint disorder NOS, Sarcoma NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074653
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.50 Year
  • Weight: 37.376 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Joint swelling Bone and joint disorder NOS Sarcoma NOS
Outcomes: Ongoing

Dog, Shepherd Dog - Australian, Male, 12.92 year, 11.79 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Tiredness (lethargy), Inappetence, Elevated blood urea nitrogen, Vomiting • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074767
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.92 Year
  • Weight: 11.790 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Tiredness (lethargy) Inappetence Elevated blood urea nitrogen Vomiting
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.